Volume 126, Issue 3, Pages 935-936 (March 2004) Reply to Horiuchi Jan H.M. Van Den Brande, Henri Braat, Sander J.H. Van Deventer, Maikel P. Peppelenbosch Gastroenterology Volume 126, Issue 3, Pages 935-936 (March 2004) DOI: 10.1053/j.gastro.2004.01.037
Figure 1 Infliximab reduces Bad phosphorylation. (A) Using a phosphoSer136 Bad reactive antiserum (Cell Signaling Technology, Beverly, MA) and Western blotting the effects of infliximab on survival signaling were investigated in MLR-stimulated human T cells as previously described.1 (B) Quantification of chemiluminescence using imaging software. Gastroenterology 2004 126, 935-936DOI: (10.1053/j.gastro.2004.01.037)